Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance

Kawakami,Kyojiro; Fujita,Yasunori; Kato,Taku; Mizutani,Kosuke; Kameyama,Koji; Tsumoto,Hiroki; Miura,Yuri; Deguchi,Takashi; Ito,Masafumi

doi:10.3892/ijo.2015.3011

Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance

Authors:
- Kyojiro Kawakami
- Yasunori Fujita
- Taku Kato
- Kosuke Mizutani
- Koji Kameyama
- Hiroki Tsumoto
- Yuri Miura
- Takashi Deguchi
- Masafumi Ito
View Affiliations

Affiliations: Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan, Department of Urology, Gifu University Graduate School of Medicine, Gifu, Gifu 501-1193, Japan
Published online on: May 18, 2015 https://doi.org/10.3892/ijo.2015.3011
Pages: 384-390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment with taxanes for castration-resistant prostate cancer often leads to the development of resistance. It has been recently demonstrated that exosomes present in the body fluids contain proteins and RNAs in the cells from which they are derived and could serve as a diagnostic marker for various diseases. In the present study, we aimed to identify proteins contained in exosomes that could be markers for progression and taxane-resistance of prostate cancer. Exosomes were isolated by differential centrifugation from the culture medium of taxane-resistant human prostate cancer PC-3 cells (PC-3R) and their parental PC-3 cells. Isolated exosomes were subjected to iTRAQ-based quantitative proteomic analysis. Exosomes were also isolated from the culture medium by using anti-CD9 antibody-conjugated magnetic beads. Protein expression was knocked down by siRNA transfection followed by analysis of the silencing effects. Proteomic analysis showed that integrin β4 (ITGB4) and vinculin (VCL) were upregulated in exosomes derived from PC-3R cells compared to PC-3 cells. The elevation of ITGB4 and VCL was confirmed in exosomes captured by anti-CD9 antibody from the culture medium of PC-3R cells. Silencing of ITGB4 and VCL expression did not affect proliferation and taxane-resistance of PC-3R cells, but ITGB4 knockdown attenuated both cell migration and invasion and VCL knockdown reduced invasion. Our results suggest that ITGB4 and VCL in exosomes could be useful markers for progression of prostate cancer associated with taxane-resistance, providing the basis for development of an exosome-based diagnostic system.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Kirby M, Hirst C and Crawford ED: Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract. 65:1180–1192. 2011. View Article : Google Scholar : PubMed/NCBI
3	Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol. 26:242–245. 2008. View Article : Google Scholar : PubMed/NCBI
4	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
5	Blagosklonny MV: NCI’s provocative questions on cancer: Some answers to ignite discussion. Oncotarget. 2:1352–1367. 2011.
6	Blagosklonny MV: Why therapeutic response may not prolong the life of a cancer patient: Selection for oncogenic resistance. Cell Cycle. 4:1693–1698. 2005. View Article : Google Scholar : PubMed/NCBI
7	Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri RW, et al: Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem. 114:1286–1293. 2013. View Article : Google Scholar
8	Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W and Geuze HJ: Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 113:3365–3374. 2000.PubMed/NCBI
9	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
10	Vlassov AV, Magdaleno S, Setterquist R and Conrad R: Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 1820:940–948. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, et al: Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 5:35912014. View Article : Google Scholar : PubMed/NCBI
12	Kojima K, Fujita Y, Nozawa Y, Deguchi T and Ito M: MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
13	Thery C, Amigorena S, Raposo G and Clayton A: Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. Chapter 3(Unit 3): 222006.
14	Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T, et al: MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 285:19076–19084. 2010. View Article : Google Scholar : PubMed/NCBI
15	Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P and Mellado B: Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 11:329–339. 2012. View Article : Google Scholar
16	Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY and Chung HC: Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat. 125:55–63. 2011. View Article : Google Scholar
17	Chien AJ and Moasser MM: Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired. Semin Oncol. 35(Suppl 2): S1–S14; quiz S39. 2008. View Article : Google Scholar : PubMed/NCBI
18	Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar
19	Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, et al: Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. J Pathol. 223:543–552. 2011. View Article : Google Scholar : PubMed/NCBI
20	Cruz-Monserrate Z, Qiu S, Evers BM and O’Connor KL: Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol. 20:656–667. 2007. View Article : Google Scholar : PubMed/NCBI
21	Geisler C, Gaisa NT, Pfister D, Fuessel S, Kristiansen G, Braunschweig T, Gostek S, Beine B, Diehl HC, Jackson AM, et al: Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. BioMed Res Int. 2015:4542562015. View Article : Google Scholar : PubMed/NCBI
22	Kumano M, Miyake H, Abolghait SK, Behnsawy HM and Fujisawa M: β4-integrin-mediated cytotoxic activity of AexU in human prostate cancer PC3 cells. Oncol Lett. 6:1482–1486. 2013.PubMed/NCBI
23	Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, et al: β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 123:682–699. 2013.PubMed/NCBI
24	Gleason B, Adley B, Rao MS and Diaz LK: Immunohistochemical detection of the beta4 integrin subunit in pancreatic adenocarcinoma. J Histochem Cytochem. 53:799–801. 2005. View Article : Google Scholar : PubMed/NCBI
25	Lipscomb EA and Mercurio AM: Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev. 24:413–423. 2005. View Article : Google Scholar : PubMed/NCBI
26	Goldmann WH, Auernheimer V, Thievessen I and Fabry B: Vinculin, cell mechanics and tumour cell invasion. Cell Biol Int. 37:397–405. 2013. View Article : Google Scholar : PubMed/NCBI
27	Srichai M and Zent R: Integrin structure and function. Cell-Extracellular Matrix Interactions in Cancer. Zent R and Pozzi A: Springer; New York: pp. 19–41. 2010, View Article : Google Scholar
28	Peng X, Nelson ES, Maiers JL and DeMali KA: New insights into vinculin function and regulation. Int Rev Cell Mol Biol. 287:191–231. 2011. View Article : Google Scholar : PubMed/NCBI
29	Banyard J, Chung I, Migliozzi M, Phan DT, Wilson AM, Zetter BR and Bielenberg DR: Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer. 14:3872014. View Article : Google Scholar : PubMed/NCBI
30	Mizutani K, Terazawa R, Kameyama K, Kato T, Horie K, Tsuchiya T, Seike K, Ehara H, Fujita Y, Kawakami K, et al: Isolation of prostate cancer-related exosomes. Anticancer Res. 34:3419–3423. 2014.PubMed/NCBI